 |
      |
|
|
|
|
|
|
|
 |
|
ALPHAGAN® P ophthalmic solution is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus.
Please click here for full Prescribing Information.
1. Verispan LLC. Vector One®: National (VONA). Yardley, PA: Verispan LLC; October 2006-December 2006. 2. Data on file, Allergan, Inc., 2007; Day; Study MA-AP01. 3. Netland PA, Mroz M, Rosner SA, Katzman B, Macy JI. Brimonidine PURITE® and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20(1):20-30. 4. Noecker RJ, Trattler W, Earl ML. Brimonidine PURITE® 0.15% versus dorzolamide 2% used as adjunctive therapy to latanoprost. Poster presented at: 17th Annual Meeting of the American Glaucoma Society; March 1-4, 2007; San Francisco, CA. 5. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007; 24(2):302-309. 6. ALPHAGAN® P Prescribing Information.
Important Safety Information
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus.
Please click here for full Prescribing Information.
1. Verispan LLC. Vector One®: National (VONA). Yardley, PA: Verispan LLC; October 2006-December 2006. 2. Data on file, Allergan, Inc., 2007; Day; Study MA-AP01. 3. Netland PA, Mroz M, Rosner SA, Katzman B, Macy JI. Brimonidine PURITE® and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20(1):20-30. 4. Noecker RJ, Trattler W, Earl ML. Brimonidine PURITE® 0.15% versus dorzolamide 2% used as adjunctive therapy to latanoprost. Poster presented at: 17th Annual Meeting of the American Glaucoma Society; March 1-4, 2007; San Francisco, CA. 5. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007; 24(2):302-309. 6. ALPHAGAN® P Prescribing Information.
©2008 Allergan, Inc., Irvine, CA 92612 | ® marks owned by Allergan, Inc. |